Talk Bio – Page 36 – Actionable Insights Powered by AI

X4 Pharma Halves Workforce in Second Round of 2025 Layoffs

2 months ago talkbio0Tagged Administration occupational activities, Changing, Chronic neutropenia, layoffs, restructuring

X4 Pharmaceuticals; layoffs; restructuring; chronic neutropenia; mavorixafor; management changes; biotech

Regeneron Prepares U.S. Submission for Garetosmab After Breakthrough Phase III Result in Ultra-Rare FOP

2 months ago talkbio0Tagged bone lesion prevention, Drugs, Orphan, fibrodysplasia, Fibrodysplasia Ossificans Progressiva, Garetosmab, Infrequent, OPTIMA trial, ossificans, Phase III, progressiva, Regeneron, Submission, United States Food and Drug Administration

Regeneron; garetosmab; FOP; fibrodysplasia ossificans progressiva; Phase III; OPTIMA trial; bone lesion prevention; rare disease; FDA submission; orphan drug

FDA Scrutinizes Telehealth Firms Like Hims for GLP-1 Drug Advertising Practices

2 months ago talkbio0Tagged Drug Compounding, Glucagon-Like Peptide 1, Hims, Super Bowl ad, Telemedicine, United States Food and Drug Administration, Weight-Loss Agents

FDA; Hims; telehealth; GLP-1; advertising; weight-loss drugs; compound drugs; Super Bowl ad; misleading claims

J&J’s Oral IL-23 Drug Icotrokinra Surpasses Sotyktu in Phase 3 Psoriasis Trials

2 months ago talkbio0Tagged Dental Plaque, deucravacitinib, IL-23 receptor antagonist, JNJ-2113, Johnson & Johnson, Myers, oral peptide, Phase 3 clinical trial, Psoriasis, skin clearance, Sotyktu

Icotrokinra; JNJ-2113; Johnson & Johnson; IL-23 receptor antagonist; Sotyktu; deucravacitinib; plaque psoriasis; Phase 3 clinical trial; skin clearance; oral peptide; Bristol Myers Squibb

FDA Cracks Down on Misleading Drug Ads in Major Pharmaceutical Companies

2 months ago talkbio0Tagged Crackdown, Misleading Drug Ads, pharmaceutical companies, United States Food and Drug Administration

FDA; Misleading Drug Ads; Pharmaceutical Companies; Crackdown

Ollin Biosciences Launches with $100M to Challenge Roche in Eye Disease Market

2 months ago talkbio0Tagged Ang2, Biosciences, Clinical Trials, Disorder of eye, Macular edema due to diabetes mellitus, Ollin, OLN324, Roche (company), Vabysmo, Vascular Endothelial Growth Factor A, Wet AMD

Ollin Biosciences; Roche; eye disease; biotech; VEGF-A; Ang2; wet AMD; diabetic macular edema; clinical trial; OLN324; Vabysmo

Eli Lilly’s Oral GLP-1 Orforglipron Outperforms Semaglutide in Diabetes and Weight Loss Trials

2 months ago talkbio0Tagged Diabetes Mellitus, Non-Insulin-Dependent, Eli Lilly, Glucagon-Like Peptide 1, Nordisk, Oral cavity, orforglipron, semaglutide, Weight Loss

Lilly; orforglipron; oral GLP-1; semaglutide; type 2 diabetes; weight loss; phase 3 trial; Novo Nordisk

Next-Generation Psoriasis Drugs Aim to Reshape Treatment Landscape

2 months ago talkbio0Tagged Approved, Clinical Trials, icotrokinra, inhibitors, interleukin-23, next-generation biologics, oral peptides, Piclidenoson, TYK2 gene, United States Food and Drug Administration, Vunakizumab

psoriasis; next-generation biologics; icotrokinra; IL-23 inhibitors; oral peptides; TYK2 inhibitors; vunakizumab; piclidenoson; clinical trials; FDA approval